Several frequently mutated residues in Ibrutinib-resistant CLL, including PLCγ2 S707, L845, D993 and M1141, are likely to impact on PLC activity via the same mechanism. The gene discussed is HSPG2; the disease is B-cell chronic lymphocytic leukemia.